Sugi Predict

Sugi Predict / Compounds / [11C]Phenethylguanidine

[11C]Phenethylguanidine

[11C]Phenethylguanidine

SCHEMBL837644

N=C(N)NCCc1ccccc1

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 4/20 0.59
▸ RAB9A P51151 4/20 0.59
▸ SMN1; SMN2 Q16637 3/20 0.59
▸ TAAR1 Q96RJ0 4/20 0.56
▸ LMNA P02545 3/20 0.56
▸ GAA P10253 2/20 0.56
▸ ALDH1A1 P00352 3/20 0.54
▸ IDO1 P14902 2/20 0.54
▸ MAOA P21397 2/20 0.54
▸ MAOB P27338 2/20 0.54
▸ CYP3A4 P08684 2/20 0.54
▸ KDM1A O60341 1/20 0.54
▸ CYP1A2 P05177 1/20 0.54
▸ HTR1A P08908 1/20 0.54
▸ ADRA2A P08913 1/20 0.54
▸ CYP2C8 P10632 1/20 0.54
▸ CYP2D6 P10635 1/20 0.54
▸ CYP2C9 P11712 1/20 0.54
▸ TSHR P16473 1/20 0.54
▸ NFKB1 P19838 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
[11C]Phenethylguanidine SCHEMBL27117673 0.98 NPC1 (0.57) NPC1RAB9ASMN1; SMN2TAAR1LMNA
[11C]Phenethylguanidine SCHEMBL28129390 0.98 NPC1 (0.57) NPC1RAB9ASMN1; SMN2TAAR1LMNA
SCHEMBL17198821 0.96 NPC1 (0.55) NPC1RAB9ASMN1; SMN2TAAR1LMNA
[11C]Phenethylguanidine SCHEMBL28305964 0.94 NPC1 (0.53) NPC1RAB9ASMN1; SMN2TAAR1LMNA
Hydrochloric Acid SCHEMBL28129397 0.94 NPC1 (0.53) NPC1RAB9ASMN1; SMN2TAAR1LMNA
[11C]Phenethylguanidine SCHEMBL5461636 0.91 ALDH1A1 (0.64) NPC1RAB9ASMN1; SMN2TAAR1LMNA
SCHEMBL17199010 0.89 MEN1 (0.50) NPC1RAB9ASMN1; SMN2TAAR1LMNA
SCHEMBL8202834 0.88 L3MBTL1 (0.58) NPC1RAB9ATAAR1GAAALDH1A1
Hydrochloric Acid SCHEMBL28129406 0.87 MEN1 (0.49) NPC1RAB9ASMN1; SMN2TAAR1LMNA
SCHEMBL21171920 0.86 TRPV1 (0.56) NPC1RAB9ALMNAALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025101904-A1 NOREPINEPHRINE TRANSPORTER-TARGETED PRODRUGS FOR CANCER THERAPY THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) 2025-05-15 — — WO claimed
CN-119950749-A Polymer-based macromolecular prodrugs 费城儿童医院 2025-05-09 — — CN claimed
US-20230174509-A1 THERAPEUTIC USE OF PLEUROMUTILINS ARIVA MED GMBH (AT) 2023-06-08 — — US claimed
EP-4135683-A1 THERAPEUTIC USE OF PLEUROMUTILINS Nabriva Therapeutics GMBH (AT) 2023-02-22 — — EP claimed
CN-115413238-A Therapeutic use of pleuromutilin compounds 纳布里瓦治疗有限责任公司 2022-11-29 — — CN claimed
US-20220160886-A1 POLYMER-BASED MACROMOLECULAR PRODRUGS THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) 2022-05-26 — — US claimed
WO-2021209596-A1 THERAPEUTIC USE OF PLEUROMUTILINS Nabriva Therapeutics GmbH (AT) 2021-10-21 — — WO claimed
EP-3852793-A1 POLYMER-BASED MACROMOLECULAR PRODRUGS The Children's Hospital Of Philadelphia (US) 2021-07-28 — — EP claimed
CN-112996533-A Polymer-based macromolecular prodrugs 费城儿童医院 2021-06-18 — — CN claimed
US-20210000967-A1 POLYMER-BASED MACROMOLECULAR PRODRUGS THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) 2021-01-07 — — US claimed
CN-105916499-B 12-epi-pleuromutilins 纳布里瓦治疗股份公司 2020-02-18 — — CN claimed
US-9701628-B2 12-epi pleuromutilins NABRIVA THERAPEUTICS AG (AT) 2017-07-11 — — US claimed
US-20170190658-A1 IMAGING AGENTS THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2017-07-06 — — US claimed
CN-106458868-A Guanidine compounds and uses thereof 伊谬诺米特医疗有限公司 2017-02-22 — — CN claimed
EP-3096751-A1 12-EPI-PLEUROMUTILINS Nabriva Therapeutics AG (AT) 2016-11-30 — — EP claimed
US-20160332963-A1 12-EPI PLEUROMUTILINS Nabriva Therapeutics GmbH (AT) 2016-11-17 — — US claimed
WO-2015110481-A1 12-EPI-PLEUROMUTILINS NABRIVA THERAPEUTICS AG (AT) 2015-07-30 — — WO claimed
US-20040024000-A1 Dihydropyrimidine derivatives as cysteine protease inhibitors NAEJA PHARMACEUTICAL INC. (CA) 2004-02-05 — — US claimed
EP-1326848-A1 DIHYDROPYRIMIDINE DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS Naeja Pharmaceutical Inc. (CA) 2003-07-16 — — EP claimed
WO-2002032879-A1 DIHYDROPYRIMIDINE DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS NAEJA PHARMACEUTICAL INC. (CA) 2002-04-25 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220160886-A1 POLYMER-BASED MACROMOLECULAR PRODRUGS PAICS, PNKP, NAMPT NPC1 1955/4885RAB9A 2529/4885SMN1; SMN2 473/4885
US-20040024000-A1 Dihydropyrimidine derivatives as cysteine protease inhibitors DPEP1, DNPEP, PEPD NPC1 1758/4885RAB9A 2309/4885SMN1; SMN2 4663/4885
US-20210000967-A1 POLYMER-BASED MACROMOLECULAR PRODRUGS PAICS, PNKP, NAMPT NPC1 1955/4885RAB9A 2529/4885SMN1; SMN2 473/4885
US-20170190658-A1 IMAGING AGENTS SLC18A1, VHL, GDI1 NPC1 558/4885RAB9A 46/4885SMN1; SMN2 887/4885
US-20160332963-A1 12-EPI PLEUROMUTILINS MLN, TCF12, PLEC NPC1 4572/4885RAB9A 1291/4885SMN1; SMN2 337/4885
US-20230174509-A1 THERAPEUTIC USE OF PLEUROMUTILINS MLN, PLEC, PELP1 NPC1 3035/4885RAB9A 1554/4885SMN1; SMN2 130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.